Two forms of familial hypercholesterolemia: Differences in cardiovascular risk factors, cardiac and extracardiac atherosclerosis;Zwei Formen familiärer Hypercholesterinämie: Unterschiede bei kardiovaskulären Risikofaktoren sowie kardialer und extrakardialer Atherosklerose

Deutsche Medizinische Wochenschrift

Volumn 139, Issue 50, 2014, Pages 2573-2577

  Vogt, A ^a   Keller, C ^a   Heigl, C ^b   Weiss, N ^c   Zollner N ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

atherosclerosis; FDB; FH; mutations

Indexed keywords

APOLIPOPROTEIN B; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN B100;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENETIC ANALYSIS; HUMAN; HYPERTENSION; INTERNAL CAROTID ARTERY; INTERNAL CAROTID ARTERY OCCLUSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SMOKING; AGED; BLOOD; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; GENETICS; GERMANY; HETEROZYGOTE DETECTION; HYPERLIPOPROTEINEMIA TYPE II; INDEL MUTATION; MYOCARDIAL INFARCTION; POINT MUTATION; RISK FACTOR; STROKE;

ADULT; AGED; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HETEROZYGOTE DETECTION; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INDEL MUTATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POINT MUTATION; RECEPTORS, LDL; RISK FACTORS; SEX FACTORS; STROKE;

EID: 84925224908     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0034-1387237     Document Type: Article

References (24)

1. Austin M. A., Hutter C. M., Zimmern R. L. et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol: 2004; 160 407 420
2. Bertolini S., Pisciotta L., Rabacchi C. et al. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy. Atherosclerosis: 2013; 227 342 348
3. Bhatnagar D., Morgan J., Siddiq S. et al. Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia. BMJ: 2000; 321 1497 1500
4. Catapano A. L., Reiner Z., De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis: 2011; 217 3 46
5. Heigl C. Genetisch charakterisierte familiäre Hypercholesterinämien: Klinische Befunde, Risikoprofil für kardiovaskuläre Komplikationen, insbesondere die koronare Herzkrankheit in einem Münchner Patientenkollektiv. Inaugural-Dissertation aus der Medizinischen Poliklinik Innenstadt des Klinikums der Universität München (Dir. Prof. Dr. D. Schlöndorff) Medizinische Fakultät LMU: 2010
6. Hobbs H. H., Leitersdorf E., Leffert C. C. et al. Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors. J Clin Invest: 1989; 84 656 664
7. Jansen A. C., van Aalst-Cohen E. S., Tanck M. W. et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med: 2004; 256 482 490
8. Keil U., Liese A. D., Hense H. W. et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J: 1998; 19 1197 1207
9. Kotseva K., Wood D., De Backer G. et al. EUROASPIRE Study Group Collaborators (152). Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet: 2009; 373 929 940
10. Leigh S. EA, Foster A. H., Whittall R. A. et al. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet: 2008; 72 485 498
11. Lloyd-Jones D. M., Leip E. P., Larson M. G. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation: 2006; 113 791 798
12. Miserez A., Keller U. Differences in the phenotypic characteristics of subjects with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arterioscler Thromb Vasc Biol: 1995; 15 719 729
13. Nordestgaard B. G., Chapman M. J., Humphries S. E. et al. for the European Atherosclerosis Society Consensus Panel Familial Hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J: 2013; 34 3478 90a
14. Schuster H., Keller C., Wolfram G. et al. Ten LDL receptor mutants explain one third of familial hypercholesterolemia in a German sample. Arterioscler Thromb Vasc Biol: 1995; 15 2176 2180
15. Schuster H., Rauh G., Müller S. et al. Allele-specific and asymmetric polymerase chain reaction amplification in combination: a one step polymerase chain reaction protocol for rapid diagnosis of familial defective apolipoprotein B-100. Anal Biochem: 1992; 204 22 25
16. Stamler J., Daviglus M. L., Garside D. B. et al. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA: 2000; 284 311 318
17. Storm R. Wahrscheinlichkeitsrechnung, mathematische Statistik und statistische Qualitätskontrolle. 6. Auflage Leipzig VEB Fachbuchverlag: 1976
18. Tatò F., Keller C., Schuster H. et al. Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia. Atherosclerosis: 1993; 101 69 77
19. Vega G. L., Grundy S. M. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest: 1986; 78 1410 1414
20. Versmissen J., Oosterveer D. M., Yazdanpanah M. et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ: 2008; 337 a2423
21. Weiss N., Binder G., Keller C. Mutations in the low-density-lipoprotein receptor gene in German patients with familial hypercholesterolaemia. J Inherit Metab Dis: 2000; 23 778 790
22. Weiss N., Eggersdorfer I., Keller C. Multiplex-PCR based single-strand conformation polymorphism protocol for simultaneous analysis of up to five fragments of the low-density-lipoprotein receptor gene. Biotechniques: 1996; 20 421 429
23. Whitfield A. J., Barrett P. H., van Bockxmeer F. M. et al. Lipid disorders and mutations in the Apo B gene. Clin Chem: 2004; 50 1725 1732
24. Williams R. R., Hunt S. C., Schumacher M. C. et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol: 1993; 72 171 176